2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014
Stay informed with AWARE data for ceftaroline regional susceptibility. Bacterial resistance continues to evolve and varies by geographical location. We know, because we've been keeping our eye on it. To keep you informed, we're offering data from the AWARE surveillance program. It's an easy was to see the susceptibility rates of ceftaroline in your region — anywhere in the country.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO was statistically superior to vancomycin plus aztreonam or to ceftriaxone.
Select a pathogen and region to show susceptibility for that region.
Select Pathogen
Select Region
TEFLARO is indicated for ABSSSI due to MRSA. It is not indicated for CABP due to MRSA.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO® (ceftaroline fosamil) was statistically superior to ceftriaxone.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO was statistically superior to ceftriaxone or vancomycin plus aztreonam.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO was statistically superior to vancomycin plus aztreonam.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO® (ceftaroline fosamil) was statistically superior to ceftriaxone.
MIC (µg/mL) |
Ceftaroline (N=1652) MIC90=0.12 |
Ceftriaxone (N=1652) MIC90=1 |
≤0.015 | 59.3 | – |
0.03 | 11.1 | – |
0.06 | 11 | 57.7 |
0.12 | 14.7 | 11.1 |
0.25 | 3.5 | 6.3 |
0.5 | 0.4* | 7 |
1 | 0.1 | 12.3* |
2 | – | 4.8 |
4 | – | 0.5 |
4 | – | 0.5 |
8 | – | 0.4 |
Total % Susceptible | 99.9% | 94.3% |
MIC (µg/mL) |
Ceftaroline (N=1652) MIC90=0.12 |
Ceftriaxone (N=1652) MIC90=1 |
≤0.015 | 59.3 | – |
0.03 | 11.1 | – |
0.06 | 11 | 57.7 |
0.12 | 14.7 | 11.1 |
0.25 | 3.5 | 6.3 |
0.5 | 0.4* | 7 |
1 | 0.1 | 12.3* |
2 | – | 4.8 |
4 | – | 0.5 |
4 | – | 0.5 |
8 | – | 0.4 |
Total % Susceptible | 99.9% | 94.3% |
FDA susceptible breakpoint.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO was statistically superior to vancomycin plus aztreonam or to ceftriaxone.
MIC (µg/mL) |
Ceftaroline (n=2995) MIC90=0.25 |
Ceftriaxone (N=2995) MIC90=4 |
Vancomycin (N=2995) MIC90=1 |
0.015 | 0 | – | – |
0.03 | 0.1 | – | – |
0.06 | 0.4 | – | – |
0.12 | 7.7 | 0.03 | – |
0.25 | 86.5 | 0 | 0.1 |
0.5 | 5.2 | 0.07 | 23.0 |
1 | 0.03* | 0.6 | 76.4 |
2 | – | 4.6 | 0.5* |
4 | – | 84.1* | – |
8 | – | 10.2 | – |
>8 | – | 0.3 | – |
Total % Susceptible |
100% | 89.5% | 100% |
MIC (µg/mL) |
Ceftaroline (N=2995) MIC90=0.25 |
Ceftriaxone (N=2995) MIC90=4 |
Vancomycin (N=2995) MIC90=1 |
0.015 | 0 | – | – |
0.03 | 0.1 | – | – |
0.06 | 0.4 | – | – |
0.12 | 7.7 | 0.03 | – |
0.25 | 86.5 | 0 | 0.1 |
0.5 | 5.2 | 0.07 | 23.0 |
1 | 0.03* | 0.6 | 76.4 |
2 | – | 4.6 | 0.5* |
4 | – | 84.1* | – |
8 | – | 10.2 | – |
>8 | – | 0.3 | – |
Total % Susceptible |
100% | 89.5% | 100% |
FDA susceptible breakpoint.
In vitro activity does not necessarily correlate with clinical results. Clinical trials did not establish that TEFLARO was statistically superior to vancomycin plus aztreonam.
MIC (µg/mL) |
Ceftaroline (N=2258) MIC90=1 |
Vancomycin (N=2258) MIC90=1 |
0.06 | 0 | 0 |
0.12 | 0.04 | 0 |
0.25 | 1.3 | 0.1 |
0.5 | 45 | 20.6 |
1 | 51.4* | 78.2 |
2 | 2.3 | 1.1* |
Total % Susceptible | 97.7% | 100% |
FDA susceptible breakpoint.
MIC (µg/mL) |
Ceftaroline (N=2258) MIC90=1 |
Vancomycin (N=2258) MIC90=1 |
0.06 | 0 | 0 |
0.12 | 0.04 | 0 |
0.25 | 1.3 | 0.1 |
0.5 | 45 | 20.6 |
1 | 51.4* | 78.2 |
2 | 2.3 | 1.1* |
Total % Susceptible | 97.7% | 100% |
FDA susceptible breakpoint.
Please click here for TEFLARO Indications and Usage and Important Safety Information.
AWARE is an ongoing worldwide surveillance program that began in 2008. The AWARE 2014 U.S. study surveyed the in vitro susceptibility activity of ceftaroline and other agents against methicillin-resistant Staphylococcus aureus, other Gram-positive and Gram-negative pathogens, including Streptococcus spp, Haemophilus spp, and Enterobacteriaceae. A total of 24,649 bacterial isolates were collected from 141 representative hospitals and medical centers distributed across all 9 U.S. Census regions from January to December 2014. Specimen type, infection site, classification of infection, and patient demographic information were documented for each bacterial isolate. Only clinically significant isolates were included, and only one isolate per patient was permitted. All body sites were considered acceptable clinical sources, and the majority came from blood (14.0%), respiratory specimens (27.6%), and skin (36.0%). The AWARE U.S. study is funded by Allergan, Inc.
This site provides a subset of data from the AWARE surveillance program. Listed here are the national and regional
susceptibilities of ceftaroline and vancomycin against skin isolates of methicillin-resistant
S. aureus (MRSA); ceftaroline and ceftriaxone against respiratory isolates of
S. pneumoniae; and ceftaroline, ceftriaxone, and vancomycin against skin and
respiratory isolates of methicillin-susceptible S. aureus (MSSA). In ceftaroline fosamil clinical trials, MRSA and MSSA
were the most frequently identified skin pathogens in the CANVAS skin infection trials, and S. pneumoniae
and MSSA were the most frequently identified respiratory pathogens in the
FOCUS pneumonia trials.
The collection and susceptibility testing of non-duplicate clinical isolates were carried out by a central laboratory (JMI Laboratories Inc.), utilizing broth microdilution susceptibility testing methods according to the Clinical and Laboratory Standards Institute (CLS) M100-525 (2015). Current breakpoints established by the FDA were used in interpreting ceftaroline susceptibility. In the tables where there are no FDA ceftaroline intermediate or resistant breakpoints available for the bacterial organisms listed, not applicable (N/A) was used. For ceftriaxone and vancomycin, CLS interpretative breakpoints were used. Tables and graphs shown in this AWARE 2014 susceptibility card focus on Staphylococcus aureus (both methicillin-susceptible and -resistant) and Streptococcus pneumoniae, since these were the most frequently identified organisms in skin infections and community-acquired pneumonia, respectively. These in vitro susceptibilities do not necessarily correlate with clinical outcomes.
In ABSSSI, TEFLARO is the first and only cephalosporin with activity against MRSA
SEE PATHOGEN COVERAGEPlease also see full Prescribing Information.
Please also see full Prescribing Information.